A recent paper in Nature shows that SARS-CoV-2 mRNA vaccination within 100 days of beginning immune checkpoint inhibitor immunotherapy improves survival of cancer patients by systemically inducing Type I interferons, suggesting that an off-the-shelf cancer vaccine that potently stimulates innate immunity may not need to be customized to contain tumor-associated antigens to be effective.
Yisimayi et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: